Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $336.56 to a high of $344.87. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $339.94 on volume of 445,000 …
Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global …
Drastic changes could be underway at Ford in the coming months as the automaker posted disappointing earnings and its stock tanked. The 115-year old company also announced Thursday that it acquired transportation software companies …
Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q …
The stock of Oracle Corporation (NYSE:ORCL) earned “Buy” rating by Credit Suisse on Thursday, October 12. Country …